Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation

References

• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Thomas X. Chemotherapy of acute leukemia in adults. Expert Opin Pharmacother. 2009;10(2):221–237. doi:10.1517/14656560802618746
   PubMed Web of Science ®Google Scholar
• Takenaka K, Onishi Y, Mori T, et al. Negative impact of cytomegalovirus reactivation on survival in adult patients with aplastic anemia after an allogeneic hematopoietic stem cell transplantation: a report from transplantation-related complication and adult aplastic anemia working groups of the Japan Society for hematopoietic cell transplantation. Transplant Cell Ther. 2021;27(1):82 e1–82 e8.
   PubMedGoogle Scholar
• Imlay HN, Kaul DR. Letermovir and maribavir for the treatment and prevention of cytomegalovirus infection in solid organ and stem cell transplant recipients. Clin Infect Dis. 2021;73(1):156–160. doi:10.1093/cid/ciaa1713
   PubMed Web of Science ®Google Scholar
• Bjorklund A, Aschan J, Labopin M, et al. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;40(11):1055–1062. doi:10.1038/sj.bmt.1705856
   PubMed Web of Science ®Google Scholar
• Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020;135(19):1619–1629. doi:10.1182/blood.2019000956
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Labopin M, Beelen D, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Blood. 2013;122(19):3359–3364. doi:10.1182/blood-2013-05-499830
   PubMed Web of Science ®Google Scholar
• Ru Y, Zhu J, Song T, et al. Features of Epstein-Barr virus and cytomegalovirus reactivation in acute leukemia patients after Haplo-HCT with myeloablative ATG-Containing conditioning regimen. Front Cell Infect Mi. 2022;12:865170.
   PubMed Web of Science ®Google Scholar
• Zhou JR, Shi DY, Wei R, et al. Co-reactivation of cytomegalovirus and Epstein-Barr virus was associated with poor prognosis after allogeneic stem cell transplantation. Front Immunol. 2020;11:620891. doi:10.3389/fimmu.2020.620891
   PubMed Web of Science ®Google Scholar
• Chawla JS, Ghobadi A, Mosley J, 3rd, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transplant Infect Dis. 2012;14(3):259–267. Jun doi:10.1111/j.1399-3062.2011.00689.x
   PubMed Web of Science ®Google Scholar
• Cesaro S, Ljungman P, Tridello G, et al. New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT. Bone Marrow Transplant. 2023;58(2):203–208. Feb doi:10.1038/s41409-022-01863-8
   PubMed Web of Science ®Google Scholar
• Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260–e272. doi:10.1016/S1473-3099(19)30107-0
   PubMed Web of Science ®Google Scholar
• Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation . Blood . 2002;99 (4) :1159 –1164 . doi:10.1182/blood.v99.4.1159
   PubMed Web of Science ®Google Scholar
• El Haddad L, Ghantoji SS, Park AK, et al. Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. J Med Virol. 2020;92(1):86–95. doi:10.1002/jmv.25574
   PubMed Web of Science ®Google Scholar
• Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett. 2014;342(1):1–8. doi:10.1016/j.canlet.2013.09.004
   PubMed Web of Science ®Google Scholar
• Chen J, Yang L, Fan Y, et al. Comparison of autologous stem cell transplantation versus haploidentical donor stem cell transplantation for favorable-and intermediate-risk acute myeloid leukemia patients in first complete remission. Biol Blood Marrow Transplant. 2018;24(4):779–788. doi:10.1016/j.bbmt.2017.12.796
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1994;15(6):825–828.
   Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956. doi:10.1016/j.bbmt.2005.09.004
   PubMed Web of Science ®Google Scholar
• Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2016;64(1):87–91. doi:10.1093/cid/ciw668
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Chou S, Einsele H, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68(8):1420–1426. doi:10.1093/cid/ciy696
   PubMed Web of Science ®Google Scholar
• Girmenia C, Lazzarotto T, Bonifazi F, et al. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: a multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. Clin Transplant. 2019;33(10):e13666.
   PubMed Web of Science ®Google Scholar
• Stern A, Su Y, Dumke H, et al. Cytomegalovirus viral load kinetics predict cytomegalovirus End-Organ disease and mortality after hematopoietic cell transplant. J Infect Dis. 2021;224(4):620–631. doi:10.1093/infdis/jiab212
   PubMed Web of Science ®Google Scholar
• Ding Y, Ru Y, Song T, et al. Epstein–Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non–Hodgkin lymphoma: the prevalence and impacts on outcomes. Ann Hematol. 2021;100(11):2773–2785. doi:10.1007/s00277-021-04642-5
   PubMed Web of Science ®Google Scholar
• Liu K, Wang Y, Han M, et al. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial. Chin Med J. 2010;123(16):2199–2205.
   PubMed Web of Science ®Google Scholar
• El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 2016;128(23):2624–2636. doi:10.1182/blood-2016-06-688432
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 2009;44(8):453–455. doi:10.1038/bmt.2009.254
   PubMed Web of Science ®Google Scholar
• Pande A, Dubberke ER. Cytomegalovirus infections of the stem cell transplant recipient and hematologic malignancy patient. Infect Dis Clin North Am. 2019;33(2):485–500. doi:10.1016/j.idc.2019.02.008
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000;44(10):2811–2815. doi:10.1128/AAC.44.10.2811-2815.2000
   PubMed Web of Science ®Google Scholar
• Einsele H, Reusser P, Bornhäuser M, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood. 2006;107(7):3002–3008. doi:10.1182/blood-2005-09-3786
   PubMed Web of Science ®Google Scholar
• Ayala E, Greene J, Sandin R, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37(9):851–856. doi:10.1038/sj.bmt.1705341
   PubMed Web of Science ®Google Scholar
• Volin L, Barkholt L, Nihtinen A, et al. editors. An open-label randomised study of oral valganciclovir versus intravenous ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Bone marrow transplantation. London: Nature Publishing Group; 2008.
   Google Scholar
• Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119–e127. doi:10.1016/S2352-3026(15)00289-6
   PubMed Web of Science ®Google Scholar
• Liu J, Kong J, Chang Y, et al. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality. Clin Microbiol Infec. 2015;21(12):1121. e9–1121. e15.
   PubMed Web of Science ®Google Scholar
• Fan ZY, Han TT, Zuo W, et al. CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT. Clin Exp Immunol. 2022;208(3):332–339. doi:10.1093/cei/uxac047
   PubMed Web of Science ®Google Scholar
• Leserer S, Bayraktar E, Trilling M, et al. Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution. Am J Hematol. 2021;96(4):436–445. doi:10.1002/ajh.26094
   PubMed Web of Science ®Google Scholar
• Broers AE, van der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell–depleted stem cell transplantation. Blood. 2000;95(7):2240–2245.
   PubMed Web of Science ®Google Scholar
• Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–2438. doi:10.1182/blood-2015-11-679639
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Stern M, Brand R, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer-Am Cancer Soc. 2009;115(20):4715–4726. doi:10.1002/cncr.24531
   Google Scholar
• Grefte A, van der Giessen M, van Son W, et al. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J Infect Dis. 1993;167(2):270–277. doi:10.1093/infdis/167.2.270
   PubMed Web of Science ®Google Scholar
• Cantoni N, Hirsch HH, Khanna N, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(9):1309–1314. doi:10.1016/j.bbmt.2010.03.020
   PubMed Web of Science ®Google Scholar
• Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99(4):1159–1164.
   PubMed Web of Science ®Google Scholar